Albireo Pharma (Albireo Pharma) Net Margin % : -384.46% (As of Sep. 2022)

View and export this data going back to 2007. Start your Free Trial

What is Albireo Pharma Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Albireo Pharma's Net Income for the three months ended in Sep. 2022 was $-37.80 Mil. Albireo Pharma's Revenue for the three months ended in Sep. 2022 was $9.83 Mil. Therefore, Albireo Pharma's net margin for the quarter that ended in Sep. 2022 was -384.46%.

The historical rank and industry rank for Albireo Pharma's Net Margin % or its related term are showing as below:

ALBO' s Net Margin % Range Over the Past 10 Years
Min: -2441400 Med: -650.86 Max: -83.86
Current: -228.51

ALBO's Net Margin % is not ranked
in the Biotechnology industry.
Industry Median: -160.92 vs ALBO: -228.51

Albireo Pharma Net Margin % Historical Data

The historical data trend for Albireo Pharma's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albireo Pharma Net Margin % Chart

Albireo Pharma Annual Data

Trend

Sep12

Sep13

Sep14

Sep15

Sep16

Dec17

Dec18

Dec19

Dec20

Dec21

Net Margin %

Get a 7-Day Free Trial

-2,441,400.00

-361.94

-650.86

-1,295.53

-83.86

Albireo Pharma Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Net Margin %	Get a 7-Day Free Trial															1,558.02	-33.71	-621.11	-486.83	-384.46

Competitive Comparison of Albireo Pharma's Net Margin %

For the Biotechnology subindustry, Albireo Pharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Albireo Pharma's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Albireo Pharma's Net Margin % distribution charts can be found below:

* The bar in red indicates where Albireo Pharma's Net Margin % falls into.

Albireo Pharma Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Albireo Pharma's Net Margin for the fiscal year that ended in Dec. 2021 is calculated as

Net Margin	=	Net Income (A: Dec. 2021 )	/	Revenue (A: Dec. 2021 )
	=	-34.03	/	40.579
	=	-83.86 %

Albireo Pharma's Net Margin for the quarter that ended in Sep. 2022 is calculated as

Net Margin	=	Net Income (Q: Sep. 2022 )	/	Revenue (Q: Sep. 2022 )
	=	-37.8	/	9.832
	=	-384.46 %

Albireo Pharma (NAS:ALBO) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Albireo Pharma Net Margin % Related Terms

Thank you for viewing the detailed overview of Albireo Pharma's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Albireo Pharma (Albireo Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albireo Pharma Inc (NAS:ALBO) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

53 State Street, 19th Floor, Boston, MA, USA, 02109

Website

https://www.albireopharma.com

Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.

Executives

Harford Simon N.r.	officer: CFO and Treasurer	AVON PRODUCTS, INC., 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Pamela Stephenson	officer: Chief Commercial Officer	C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Martha J. Carter	officer: Chief Regulatory Officer	C/O AEGERION PHARMACEUTICALS, INC., 89 HEADQUARTERS PLAZA, SUITE 1212, MORRISTOWN NJ 07960
Jan Mattsson	officer: Chief Operating Officer	C/O ALBIREO PHARMA, INC., 50 MILK STREET, 16TH FLOOR, BOSTON MA 02109
Cooper Ronald Harold Wilfred	director, officer: President and CEO	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Michelle Graham	officer: Chief Human Resources Officer	10000 WEHRLE DRIVE, CLARENCE NY 14031
Jason Duncan	officer: General Counsel	C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109
Paul Streck	officer: Chief Medical Officer	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Craig C. Hopkinson	director	852 WINTER STREET, WALTHAM MA 02451
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Susan Alesina	director	C/O ALBIREO PHARMA, INC., 53 STATE STREET, 19TH FLOOR, BOSTON MA 02109
Habib J Dable	director	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Patrick Taylor Horn	officer: Chief Medical Officer	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003